Login to Your Account

Dezima team regroups in startup Northsea to advance NASH candidate

By Nuala Moran
Staff Writer

Tuesday, December 12, 2017

LONDON – Newco Northsea Therapeutics BV has sailed onto the scene with a portfolio of structurally engineered fatty acids and a €25 million series A funding round to take the lead product, icosabutate (PRC-4016), through phase IIb in the treatment of NASH.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription